Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2026)

Amneal Pharmaceuticals' Capital Expenditures history runs 10 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 37.89% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $65.1 million (up 16.44% YoY), while the FY2025 annual figure was $70.1 million, up 34.93% from the prior year.
• Capital Expenditures was $8.2 million for Q1 2026 at Amneal Pharmaceuticals, down from $21.8 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $22.8 million in Q2 2025 to a low of $5.0 million in Q2 2022.
• Historically, Capital Expenditures has averaged $12.9 million across 5 years, with a median of $11.7 million in 2023.
• Biggest YoY gain for Capital Expenditures was 137.73% in 2023; the steepest drop was 38.95% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $11.5 million in 2022, then declined by 13.96% to $9.9 million in 2023, then jumped by 53.62% to $15.2 million in 2024, then surged by 43.67% to $21.8 million in 2025, then tumbled by 62.45% to $8.2 million in 2026.
• The last three Capital Expenditures figures came in at $8.2 million (Q1 2026), $21.8 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.